Tarsus Pharmaceuticals, Inc.
TARS
$46.47
$2.906.66%
| Weiss Ratings | TARS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | TARS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Good | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | TARS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.61 | |||
| Price History | TARS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 9.19% | |||
| 30-Day Total Return | -5.40% | |||
| 60-Day Total Return | -10.27% | |||
| 90-Day Total Return | 19.49% | |||
| Year to Date Total Return | -15.74% | |||
| 1-Year Total Return | 30.90% | |||
| 2-Year Total Return | 206.53% | |||
| 3-Year Total Return | 144.58% | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -23.94% | |||
| 52-Week Low % Change | 116.96% | |||
| Price | TARS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $57.28 | |||
| 52-Week Low Price | $20.08 | |||
| 52-Week Low Price (Date) | Aug 05, 2024 | |||
| 52-Week High Price (Date) | Feb 05, 2025 | |||
| Valuation | TARS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 1.67B | |||
| Enterprise Value | 1.45B | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -3.10 | |||
| Earnings Per Share Growth | -33.18% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 9.18 | |||
| Price/Book (Q) | 7.44 | |||
| Enterprise Value/Revenue (TTM) | 7.94 | |||
| Price | $46.47 | |||
| Enterprise Value/EBITDA (TTM) | -12.18 | |||
| Enterprise Value/EBIT | -12.05 | |||
| Market Cap Category | Small Cap | |||
| Dividends and Shares | TARS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 38.56M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | TARS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 949 409 1801 | |||
| Address | 15440 Laguna Canyon Road Irvine, CA 92618 | |||
| Website | www.tarsusrx.com | |||
| Country | United States | |||
| Year Founded | 2016 | |||
| Profitability | TARS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -65.90% | |||
| Profit Margin | -63.16% | |||
| Management Effectiveness | TARS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -23.46% | |||
| Return on Equity | -- | |||
| Income Statement | TARS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 182.95M | |||
| Total Revenue (TTM) | 182.95M | |||
| Revenue Per Share | $4.74 | |||
| Gross Profit (TTM) | 128.81M | |||
| EBITDA (TTM) | -119.34M | |||
| EBIT (TTM) | -120.57M | |||
| Net Income (TTM) | -115.55M | |||
| Net Income Avl. to Common (TTM) | -115.55M | |||
| Total Revenue Growth (Q YOY) | 407.86% | |||
| Earnings Growth (Q YOY) | 44.84% | |||
| EPS Diluted (TTM) | -3.10 | |||
| EPS Diluted Growth (Q YOY) | 54.30% | |||
| Balance Sheet | TARS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 291.38M | |||
| Cash Per Share (Q) | $7.56 | |||
| Total Current Assets (Q) | 356.71M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 224.53M | |||
| Current Ratio (Q) | 4.425 | |||
| Book Value Per Share (Q) | $5.85 | |||
| Total Assets (Q) | 376.99M | |||
| Total Current Liabilities (Q) | 80.61M | |||
| Total Debt (Q) | 72.45M | |||
| Total Liabilities (Q) | 152.46M | |||
| Total Common Equity (Q) | 224.53M | |||
| Cash Flow | TARS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -199.20M | |||
| Cash from Financing (TTM) | 154.66M | |||
| Net Change in Cash (TTM) | -127.57M | |||
| Levered Free Cash Flow (TTM) | -50.48M | |||
| Cash from Operations (TTM) | -83.03M | |||
